论文部分内容阅读
目的:探讨雾化吸入氨溴索对高原地区慢性阻塞性肺疾病(COPD)急性加重期患者的临床疗效。方法:选取80例COPD急性加重期患者,随机分对照组与干预组,各40例。两组均采用氧化驱动雾化吸入治疗,对照组雾化剂为α-靡蛋白酶与生理盐水;干预组雾化剂为盐酸氨溴索与生理盐水,对比两组疗效。结果:对照组治疗总有效率为80.0%,干预组为92.5%,组间差异显著(P<0.05)。干预组临床症状与体征平均消失时间明显短于对照组(P<0.05)。结论:氨溴索雾化吸入治疗对COPD急性加重期患者疗效显著,值得在高原地区推广应用。
Objective: To investigate the clinical effect of inhalation of ambroxol on patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) in the plateau area. Methods: Eighty patients with acute exacerbation of COPD were randomly divided into control group and intervention group, 40 cases in each group. The two groups were treated with oxidation-driven inhalation therapy, the control group of atomization agent is α-extravertase and saline; the intervention group atomization agent ambroxol hydrochloride and saline, compared the two groups. Results: The total effective rate was 80.0% in the control group and 92.5% in the intervention group, with significant difference (P <0.05). Intervention group clinical symptoms and signs disappeared significantly shorter than the control group (P <0.05). Conclusion: Ambroxol inhalation therapy has a significant effect on patients with acute exacerbation of COPD and is worth popularizing in the plateau.